Cognition initiates CT1812 trial in U.S.
Cognition Therapeutics has initiated testing of CT1812 in clinical trials in the United States. Read More »
Merck releases KEYNOTE-013 KEYTRUDA data
Merck recently released KEYTRUDA data demonstrating an overall response rate of 41 percent in patients with relapsed or refractory primary mediastinal large B-cell lymphoma. Read More »
FDA grants velusetrag with Fast Track designation
Theravance Biopharma's velusetrag (TD-5108) has been granted Fast Track designation by the U.S. Food and Drug Administration. Read More »
Risankizumab granted Orphan Drug Designation by FDA
AbbVie's risankizumab has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the investigational treatment of pediatric patients who have Crohn’s disease. Read More »
Otsuka ABILIFY MAINENA sNDA under review by FDA
Otsuka Pharmaceuticals and Lundbeck's supplemental New Drug Application for the expanded labeling of ABILIFY MAINENA has been completed and will receive a substantive review by the U.S. Food and Drug Administration. Read More »
Biological Industries receives FDA approval for NutriStem
Biological Industries' Drug Master File for NutriStem hPSC XF Medium has been accepted by the U.S. Food and Drug Administration. Read More »
FDA approves Armodafinil Tablets in U.S.
The U.S. Food and Drug Administration has approved Armodafinil Tablets developed by Lupin Pharmaceuticals. Read More »
Intarcia submits ITCA 650 application to FDA
Intarcia Therapeutics has submitted its New Drug Application (NDA) for ITCA 650 to the U.S. Food and Drug Administration. Read More »
Abbvie’s valiparib granted Orphan Drug Designation
AbbVie's oral poly polymerase inhibitor valiparib has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. Read More »
FDA accepts BLA for human anti-rabies lgG therapy
Kedrion Biopharma and Kamada's Biologics License Application for human anti-rabies immunoglobulin therapy has been accepted for review by the U.S. Food and Drug Administration. Read More »
FDA approves Allergan’s RESTASIS MULTIDOSE
The Food and Drug Administration has approved Allergan's RESTASIS MULTIDOSE, its bottled version of RESTASIS, both of which are free of preservatives. Read More »
FDA approves XTANDI label update
Astellas Pharma and Pfizer's joint-supplemental New Drug Application that will see the update of the XTANDI capsules product label has been approved by the Food and Drug Administration. Read More »
New report shows continuing savings of generic drugs
According to a new report released by the 2016 Generic Drug Savings and Access in the United States, generic prescription drugs generated 328 percent increase in annual savings since 2005. Read More »
More prescription coupons, discounts driving up costs, expert argues
Co-pay coupons and discounts offered to consumers ultimately will lead to higher costs across society as they increasingly drive up premiums, according to one leading expert on prescription drugs. Read More »
Coupons for brand-name drugs are misleading, experts say
At first, price-slashing discount coupons for expensive drugs may appeal to consumers on an everyday basis, but a look behind the scenes suggests that using brand-name medications may possibly yield little, if any, net savings. Read More »
Alerts Sign-up